GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (MEX:FGEN) » Definitions » Cyclically Adjusted PB Ratio

FibroGen (MEX:FGEN) Cyclically Adjusted PB Ratio : 0.37 (As of Jun. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Cyclically Adjusted PB Ratio?

As of today (2024-06-25), FibroGen's current share price is MXN20.14. FibroGen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was MXN53.75. FibroGen's Cyclically Adjusted PB Ratio for today is 0.37.

The historical rank and industry rank for FibroGen's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEX:FGEN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 0.49   Max: 6.84
Current: 0.31

During the past years, FibroGen's highest Cyclically Adjusted PB Ratio was 6.84. The lowest was 0.11. And the median was 0.49.

MEX:FGEN's Cyclically Adjusted PB Ratio is ranked better than
78.05% of 656 companies
in the Biotechnology industry
Industry Median: 1.615 vs MEX:FGEN: 0.31

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

FibroGen's adjusted book value per share data for the three months ended in Mar. 2024 was MXN-38.060. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN53.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for FibroGen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted PB Ratio Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.47 0.24

FibroGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 0.73 0.24 0.24 0.65

Competitive Comparison of FibroGen's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted PB Ratio falls into.



FibroGen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

FibroGen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=20.14/53.75
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroGen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, FibroGen's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-38.06/131.7762*131.7762
=-38.060

Current CPI (Mar. 2024) = 131.7762.

FibroGen Quarterly Data

Book Value per Share CPI Adj_Book
201406 -44.906 100.560 -58.846
201409 -53.777 100.428 -70.563
201412 55.308 99.070 73.567
201503 47.487 99.621 62.815
201506 65.915 100.684 86.270
201509 59.955 100.392 78.698
201512 49.255 99.792 65.041
201603 43.280 100.470 56.766
201606 56.919 101.688 73.761
201609 54.671 101.861 70.727
201612 50.466 101.863 65.286
201703 38.493 102.862 49.313
201706 58.606 103.349 74.726
201709 126.770 104.136 160.418
201712 125.807 104.011 159.390
201803 108.786 105.290 136.152
201806 115.664 106.317 143.362
201809 103.903 106.507 128.555
201812 117.030 105.998 145.491
201903 110.182 107.251 135.378
201906 139.130 108.070 169.650
201909 134.565 108.329 163.690
201912 111.050 108.420 134.973
202003 120.901 108.902 146.296
202006 101.272 108.767 122.695
202009 109.783 109.815 131.738
202012 91.840 109.897 110.124
202103 82.359 111.754 97.114
202106 56.011 114.631 64.388
202109 72.258 115.734 82.274
202112 46.193 117.630 51.748
202203 33.733 121.301 36.646
202206 22.274 125.017 23.478
202209 5.633 125.227 5.928
202212 -4.440 125.222 -4.672
202303 -9.113 127.348 -9.430
202306 -17.854 128.729 -18.277
202309 -27.839 129.860 -28.250
202312 -35.087 129.419 -35.726
202403 -38.060 131.776 -38.060

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (MEX:FGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


FibroGen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (MEX:FGEN) Business Description

Industry
Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.